Lee's Pharmaceutical of Hong Kong assumed responsibility for expanding into China a Phase III trial of a cardiovascular drug. In exchange, Lee’s will have an option to negotiate China rights for the drug. The drug, an anticoagulant called betrixaban, was developed by Portola Pharmaceuticals of San Francisco. Lee's will make upfront and continuing payments to Portola, which will support the China arm of the Phase III trial. Once the trial is concluded, Lee's will have an exclusive period – the duration was not specified – to negotiate China rights for betrixaban. More details.... Stock Symbol: (HK: 0950) Share this with colleagues: // //